FDA Approves Pembrolizumab for PD-L1-Positive Ovarian Cancer

from TheBrief.Health · host TheBrief.Health

FDA approves pembrolizumab combinations for PD-L1–positive, platinum-resistant ovarian cancer, improving progression-free and overall survival, offering new hope for patients with limited treatment options.

Episode metadata supplied by the publisher feed · Published Feb 19, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

FDA Approves Pembrolizumab for PD-L1-Positive Ovarian Cancer

0:00 1:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on February 19, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!